BioCentury
ARTICLE | Company News

BLA delay for Xoma and Baxter

April 25, 2000 7:00 AM UTC

The FDA told XOMA and partner BAX that data from their Phase III trial of Neuprex to treat meningococcemia were not sufficient to support the filing of a BLA. The FDA's decision comes as no surprise, ...